2020
Initiation of Angiotensin-Neprilysin Inhibition After Acute Decompensated Heart Failure
DeVore AD, Braunwald E, Morrow DA, Duffy CI, Ambrosy AP, Chakraborty H, McCague K, Rocha R, Velazquez EJ. Initiation of Angiotensin-Neprilysin Inhibition After Acute Decompensated Heart Failure. JAMA Cardiology 2020, 5: 202-207. PMID: 31825471, PMCID: PMC6990764, DOI: 10.1001/jamacardio.2019.4665.Peer-Reviewed Original ResearchMeSH KeywordsAcute DiseaseAgedAminobutyratesAngiotensin Receptor AntagonistsAngiotensin-Converting Enzyme InhibitorsBiphenyl CompoundsDrug CombinationsEnalaprilFemaleHeart FailureHospitalizationHumansMaleMiddle AgedNatriuretic Peptide, BrainNeprilysinPatient DischargePeptide FragmentsTetrazolesValsartanConceptsAcute decompensated heart failureSacubitril/valsartanNT-proBNP levelsDecompensated heart failureOpen-label studyReduced ejection fractionHospital initiationHeart failurePIONEER-HFEjection fractionWeek 8N-terminal pro-B-type natriuretic peptide levelsPro-B-type natriuretic peptide levelsOpen-label extension phaseAngiotensin-Neprilysin InhibitionHeart failure rehospitalizationPIONEER-HF trialWeek 8 visitNatriuretic peptide levelsActive-controlled trialCardiovascular deathComposite outcomeHemodynamic stabilityRecent hospitalizationClinical outcomes
2019
Biomarker Profile of Left Atrial Myopathy in Heart Failure With Preserved Ejection Fraction: Insights From the RELAX Trial
Patel RB, Alenezi F, Sun JL, Alhanti B, Vaduganathan M, Oh JK, Redfield MM, Butler J, Hernandez AF, Velazquez EJ, Shah SJ. Biomarker Profile of Left Atrial Myopathy in Heart Failure With Preserved Ejection Fraction: Insights From the RELAX Trial. Journal Of Cardiac Failure 2019, 26: 270-275. PMID: 31857197, PMCID: PMC7078046, DOI: 10.1016/j.cardfail.2019.12.001.Peer-Reviewed Original ResearchMeSH KeywordsAtrial Function, LeftBiomarkersHeart FailureHumansMuscular DiseasesNatriuretic Peptide, BrainPeptide FragmentsStroke VolumeConceptsLA reservoir strainLA myopathyHeart failureNT-proBNPEjection fractionLA reservoirReservoir strainLA strainN-terminal pro-B-type natriuretic peptidePro-B-type natriuretic peptideAtrial mechanical dysfunctionEjection Fraction trialLA contractile strainLower LA reservoirJugular venous pressurePoor clinical outcomePhosphodiesterase-5 inhibitionAssociation of LAAtrial myopathyBaseline echocardiogramRELAX trialNeurohormonal activationExercise capacityVenous pressureClinical outcomesClinical Outcomes in Patients With Acute Decompensated Heart Failure Randomly Assigned to Sacubitril/Valsartan or Enalapril in the PIONEER-HF Trial
Morrow DA, Velazquez EJ, DeVore AD, Desai AS, Duffy CI, Ambrosy AP, Gurmu Y, McCague K, Rocha R, Braunwald E. Clinical Outcomes in Patients With Acute Decompensated Heart Failure Randomly Assigned to Sacubitril/Valsartan or Enalapril in the PIONEER-HF Trial. Circulation 2019, 139: 2285-2288. PMID: 30955360, DOI: 10.1161/circulationaha.118.039331.Peer-Reviewed Original Research
2018
Angiotensin–Neprilysin Inhibition in Acute Decompensated Heart Failure
Velazquez EJ, Morrow DA, DeVore AD, Duffy CI, Ambrosy AP, McCague K, Rocha R, Braunwald E. Angiotensin–Neprilysin Inhibition in Acute Decompensated Heart Failure. New England Journal Of Medicine 2018, 380: 539-548. PMID: 30415601, DOI: 10.1056/nejmoa1812851.Peer-Reviewed Original ResearchMeSH KeywordsAcute DiseaseAgedAminobutyratesAngiotensin Receptor AntagonistsAngiotensin-Converting Enzyme InhibitorsBiphenyl CompoundsCardiac Output, LowDose-Response Relationship, DrugDouble-Blind MethodDrug CombinationsEnalaprilFemaleHeart FailureHumansMaleMiddle AgedNatriuretic Peptide, BrainNeprilysinPeptide FragmentsStroke VolumeTetrazolesValsartanConceptsAcute decompensated heart failureDecompensated heart failureNT-proBNP concentrationsSacubitril-valsartan groupSacubitril-valsartan therapyReduced ejection fractionHeart failureSymptomatic hypotensionRenal functionEnalapril groupEjection fractionWeek 4N-terminal pro-B-type natriuretic peptide concentrationsAngiotensin-Neprilysin InhibitionKey safety outcomePrimary efficacy outcomeNatriuretic peptide concentrationsGreater reductionEnalapril therapyEfficacy outcomesHemodynamic stabilizationSafety outcomesBaseline valuesWeek 1PatientsRationale and design of the comParIson Of sacubitril/valsartaN versus Enalapril on Effect on nt-pRo-bnp in patients stabilized from an acute Heart Failure episode (PIONEER-HF) trial
Velazquez EJ, Morrow DA, DeVore AD, Ambrosy AP, Duffy CI, McCague K, Hernandez AF, Rocha RA, Braunwald E. Rationale and design of the comParIson Of sacubitril/valsartaN versus Enalapril on Effect on nt-pRo-bnp in patients stabilized from an acute Heart Failure episode (PIONEER-HF) trial. American Heart Journal 2018, 198: 145-151. PMID: 29653636, DOI: 10.1016/j.ahj.2018.01.004.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, OralAgedAminobutyratesBiphenyl CompoundsCardiac Output, LowCause of DeathDose-Response Relationship, DrugDouble-Blind MethodDrug Administration ScheduleDrug CombinationsDrug Delivery SystemsEnalaprilFemaleHeart FailureHumansMaleMiddle AgedNatriuretic Peptide, BrainPatient SafetyPeptide FragmentsPrognosisProspective StudiesRisk AssessmentSeverity of Illness IndexSurvival RateTetrazolesTreatment OutcomeValsartanConceptsAcute decompensated heart failureSacubitril/valsartanB-type natriuretic peptideDecompensated heart failureAmino-terminal pro-B-type natriuretic peptideTerminal pro-B-type natriuretic peptideEjection fractionHeart failureHospital initiationNatriuretic peptideEnd pointClass angiotensin receptor neprilysin inhibitorAngiotensin receptor neprilysin inhibitorPg/Primary efficacy end pointAmbulatory HF patientsExploratory end pointsPIONEER-HF trialEfficacy end pointReduced ejection fractionSafety end pointOpen-label treatmentIncidence of angioedemaYears of agePIONEER-HF
2017
Sudden cardiac death after acute heart failure hospital admission: insights from ASCEND‐HF
Pokorney SD, Al‐Khatib S, Sun J, Schulte P, O'Connor CM, Teerlink JR, Armstrong PW, Ezekowitz JA, Starling RC, Voors AA, Velazquez EJ, Hernandez AF, Mentz RJ. Sudden cardiac death after acute heart failure hospital admission: insights from ASCEND‐HF. European Journal Of Heart Failure 2017, 20: 525-532. PMID: 29266564, DOI: 10.1002/ejhf.1078.Peer-Reviewed Original ResearchConceptsSudden cardiac deathVT/VFHeart failure hospital admissionsAcute HFCardiac deathHospital admissionVentricular tachycardia/ventricular fibrillationDecompensated Heart Failure (ASCEND-HF) trialChronic obstructive pulmonary diseaseVT/VF eventsEvent ratesComposite event rateMeier event ratesHeart Failure TrialCause mortality ratesDay of admissionObstructive pulmonary diseaseLonger QRS durationCause mortalityBaseline characteristicsComposite endpointEjection fractionPulmonary diseaseASCEND-HFFailure TrialImpaired left ventricular global longitudinal strain in patients with heart failure with preserved ejection fraction: insights from the RELAX trial
DeVore AD, McNulty S, Alenezi F, Ersboll M, Vader JM, Oh JK, Lin G, Redfield MM, Lewis G, Semigran MJ, Anstrom KJ, Hernandez AF, Velazquez EJ. Impaired left ventricular global longitudinal strain in patients with heart failure with preserved ejection fraction: insights from the RELAX trial. European Journal Of Heart Failure 2017, 19: 893-900. PMID: 28194841, PMCID: PMC5511088, DOI: 10.1002/ejhf.754.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overBiomarkersDouble-Blind MethodEchocardiographyExercise ToleranceFemaleFollow-Up StudiesHeart Failure, SystolicHeart VentriclesHumansMaleMiddle AgedMyocardial ContractionNatriuretic Peptide, BrainOxygen ConsumptionPeptide FragmentsProcollagenQuality of LifeRetrospective StudiesStroke VolumeTime FactorsVentricular Function, LeftConceptsLV global longitudinal strainGlobal longitudinal strainImpaired LV global longitudinal strainVentricular global longitudinal strainEjection fractionQuality of lifeRELAX trialExercise capacityHeart failureN-terminal pro-brain natriuretic peptideLeft ventricular global longitudinal strainWorse LV global longitudinal strainLog-transformed NT-proBNPPro-brain natriuretic peptideNormal LV ejection fractionLongitudinal strainHeart failure scoreLV ejection fractionPeak oxygen consumptionHFpEF patientsMinnesota LivingDiastolic dysfunctionNT-proBNPSystolic dysfunctionClinical characteristicsSudden Cardiac Death in Patients With Ischemic Heart Failure Undergoing Coronary Artery Bypass Grafting
Rao MP, Al-Khatib SM, Pokorney SD, She L, Romanov A, Nicolau JC, Lee KL, Carson P, Selzman CH, Stepinska J, Cleland JG, Tungsubutra W, Desvigne-Nickens PM, Sueta CA, Siepe M, Lang I, Feldman AM, Yii M, Rouleau JL, Velazquez EJ. Sudden Cardiac Death in Patients With Ischemic Heart Failure Undergoing Coronary Artery Bypass Grafting. Circulation 2017, 135: 1136-1144. PMID: 28154006, PMCID: PMC5516272, DOI: 10.1161/circulationaha.116.026075.Peer-Reviewed Original ResearchMeSH KeywordsAgedAtrial FibrillationCoronary Artery BypassDeath, Sudden, CardiacFemaleFollow-Up StudiesHeart FailureHumansHydroxymethylglutaryl-CoA Reductase InhibitorsIncidenceMaleMiddle AgedMultivariate AnalysisNatriuretic Peptide, BrainPostoperative PeriodProportional Hazards ModelsReceptors, Tumor Necrosis FactorRisk FactorsStroke VolumeVentricular Function, LeftConceptsCoronary artery bypass graft surgerySudden cardiac deathEnd-systolic volume indexB-type natriuretic peptideVentricular ejection fractionSurgical ventricular reconstructionCardiac deathEjection fractionHeart failureNatriuretic peptideVentricular reconstructionPreoperative end-systolic volume indexLow left ventricular ejection fractionIncidence of SCDPredictors of SCDArtery bypass graft surgeryCoronary Artery Bypass GraftingLeft ventricular ejection fractionVolume indexArtery Bypass GraftingBypass graft surgeryIschemic heart failureContemporary clinical trialsBlinded committeeSTICH trial
2016
Metabolomic Profiling Identifies Novel Circulating Biomarkers of Mitochondrial Dysfunction Differentially Elevated in Heart Failure With Preserved Versus Reduced Ejection Fraction: Evidence for Shared Metabolic Impairments in Clinical Heart Failure
Hunter WG, Kelly JP, McGarrah RW, Khouri MG, Craig D, Haynes C, Ilkayeva O, Stevens RD, Bain JR, Muehlbauer MJ, Newgard CB, Felker GM, Hernandez AF, Velazquez EJ, Kraus WE, Shah SH. Metabolomic Profiling Identifies Novel Circulating Biomarkers of Mitochondrial Dysfunction Differentially Elevated in Heart Failure With Preserved Versus Reduced Ejection Fraction: Evidence for Shared Metabolic Impairments in Clinical Heart Failure. Journal Of The American Heart Association 2016, 5: e003190. PMID: 27473038, PMCID: PMC5015273, DOI: 10.1161/jaha.115.003190.Peer-Reviewed Original ResearchConceptsLeft ventricular ejection fractionReduced ejection fractionEjection fractionHF controlsHFpEF casesHeart failureMetabolic impairmentVersus Reduced Ejection FractionHistory of HFNormal diastolic functionNovel circulating biomarkersClinical heart failureVentricular ejection fractionDiastolic dysfunction gradeHeart failure pathogenesisStrict inclusion criteriaFatty acid oxidationLVEF spectrumCardiac catheterizationDiastolic functionHF diagnosisSequential patientsMetabolic abnormalitiesInsulin resistanceCirculating Biomarkers
2015
Isosorbide Mononitrate in Heart Failure with Preserved Ejection Fraction
Redfield MM, Anstrom KJ, Levine JA, Koepp GA, Borlaug BA, Chen HH, LeWinter MM, Joseph SM, Shah SJ, Semigran MJ, Felker GM, Cole RT, Reeves GR, Tedford RJ, Tang WH, McNulty SE, Velazquez EJ, Shah MR, Braunwald E. Isosorbide Mononitrate in Heart Failure with Preserved Ejection Fraction. New England Journal Of Medicine 2015, 373: 2314-2324. PMID: 26549714, PMCID: PMC4712067, DOI: 10.1056/nejmoa1510774.Peer-Reviewed Original ResearchConceptsHeart failureEjection fractionIsosorbide mononitratePlacebo groupDose regimensWalk distanceLife scoresN-terminal pro-brain natriuretic peptidePro-brain natriuretic peptideEnd pointSignificant between-group differencesIsosorbide mononitrate groupLow daily activityNT-proBNP levelsPrimary end pointSecondary end pointsSubmaximal exercise capacityDose-escalation regimenHours of activityActivity levelsBetween-group differencesDaily activity levelsDaily activitiesActivity toleranceExercise capacity
2013
Low-Dose Dopamine or Low-Dose Nesiritide in Acute Heart Failure With Renal Dysfunction: The ROSE Acute Heart Failure Randomized Trial
Chen HH, Anstrom KJ, Givertz MM, Stevenson LW, Semigran MJ, Goldsmith SR, Bart B, Bull DA, Stehlik J, LeWinter MM, Konstam MA, Huggins GS, Rouleau JL, O'Meara E, Tang WH, Starling RC, Butler J, Deswal A, Felker GM, O'Connor CM, Bonita RE, Margulies KB, Cappola TP, Ofili EO, Mann DL, Dávila-Román VG, McNulty SE, Borlaug BA, Velazquez EJ, Lee KL, Shah MR, Hernandez AF, Braunwald E, Redfield MM. Low-Dose Dopamine or Low-Dose Nesiritide in Acute Heart Failure With Renal Dysfunction: The ROSE Acute Heart Failure Randomized Trial. JAMA 2013, 310: 2533-2543. PMID: 24247300, PMCID: PMC3934929, DOI: 10.1001/jama.2013.282190.Peer-Reviewed Original ResearchConceptsLow-dose dopamineAcute heart failureCumulative urine volumeRenal dysfunctionCystatin C levelsHeart failureRenal functionUrine volumeDiuretic therapyPlacebo-controlled clinical trialEnd pointPooled placebo groupCoprimary end pointsSecondary end pointsHours of admissionC levelsSerum cystatin CDose dopaminePlacebo groupActive treatmentClinical outcomesRandomized trialsClinical trialsCystatin CMAIN OUTCOMEPrognostic Significance of Biomarkers in Predicting Outcome in Patients With Coronary Artery Disease and Left Ventricular Dysfunction
Feldman AM, Mann DL, She L, Bristow MR, Maisel AS, McNamara DM, Walsh R, Lee DL, Wos S, Lang I, Wells G, Drazner MH, Schmedtje JF, Pauly DF, Sueta CA, Di Maio M, Kron IL, Velazquez EJ, Lee KL. Prognostic Significance of Biomarkers in Predicting Outcome in Patients With Coronary Artery Disease and Left Ventricular Dysfunction. Circulation Heart Failure 2013, 6: 461-472. PMID: 23584092, PMCID: PMC3905743, DOI: 10.1161/circheartfailure.112.000185.Peer-Reviewed Original ResearchConceptsCoronary artery bypassPrimary end pointCoronary artery diseaseIndependent prognostic informationArtery bypassMultivariable analysisPrognostic informationSTNFR-1Artery diseaseClinical factorsPlasma levelsUnivariate analysisIschemic Heart Failure (STICH) trialEnd pointSoluble tumor necrosisHeart Failure TrialLeft ventricular reconstructionPrimary outcome variableNet reclassification improvementAbility of biomarkersSubstudy patientsVentricular dysfunctionCardiac hospitalizationBiomarker substudyHeart failure